OLIG2 Antibody

What is OLIG2 and why is it important in neuroscience research?

OLIG2 (Oligodendrocyte transcription factor 2) is a basic helix-loop-helix (bHLH) transcription factor essential for oligodendrocyte and motor neuron specification in the spinal cord . It plays critical roles in:

• Oligodendrocyte lineage determination and differentiation

• Motor neuron development in the hindbrain

• Establishment of the pMN domain in the embryonic neural tube (in cooperation with OLIG1)

• Antagonism of V2 interneuron and NKX2-2-induced V3 interneuron development

OLIG2 is also implicated in the brain's response to cortical injury through post-injury gliosis and is highly expressed in malignant gliomas, where it contributes to tumor progression .

How do I select the appropriate OLIG2 antibody for my specific application?

Selection depends on several experimental factors:

For cross-species studies, select antibodies validated in your target species. Many OLIG2 antibodies work across human, mouse, and rat samples due to sequence conservation .

What are the optimal protocols for OLIG2 immunohistochemistry in FFPE tissue sections?

For successful OLIG2 immunohistochemistry in formalin-fixed paraffin-embedded (FFPE) tissues:

• Antigen retrieval: Heat-induced epitope retrieval using citrate buffer (10 mmol/L, pH 6.0) at 120°C for 10 minutes provides optimal results

• Primary antibody incubation: Recommended dilutions range from 1:50-1:1000 depending on the specific antibody

• Visualization systems: Both DAB-based chromogenic and fluorescence detection work well

• Controls: Include normal brain tissue with oligodendrocytes of interfascicular, perivascular, and perineuronal disposition as positive controls

Studies show remarkable improvement in OLIG2 detection following heat-induced antigen retrieval, particularly with citrate buffer compared to PBS .

How can I perform successful double immunolabeling with OLIG2 and other cell-type markers?

For co-localization studies with OLIG2 and other markers:

• Sequential staining approach:

  • Complete OLIG2 immunostaining first

  • Treat slides in 0.1 mol/L glycine (pH 2.0) for 1 hour at room temperature to remove the primary-secondary antibody complex

  • Perform secondary immunostaining with markers like GFAP or MBP

• Simultaneous staining approach:

  • Use primary antibodies from different host species (e.g., goat anti-OLIG2 with mouse anti-O4)

  • Incubate tissue with both primaries for 3 hours at room temperature

  • Visualize using spectrally distinct fluorophores (e.g., NorthernLights™ 637 for OLIG2)

This technique reveals that OLIG2 and GFAP are expressed in a mutually exclusive manner in normal brain tissue .

What methods can I use to quantify OLIG2 expression levels?

Quantification approaches for OLIG2 expression include:

• Cell counting in tissue sections:

  • Count OLIG2-positive nuclei in defined regions of interest

  • Express as percentage of total DAPI-positive nuclei

  • Compare across experimental conditions using statistical tests (e.g., Student's t-test)

• Western blot densitometry:

  • Use recombinant human OLIG2 as positive control

  • Quantify band intensity at ~32 kDa

• Flow cytometry:

  • Perform intracellular staining following fixation and permeabilization

  • Analyze percentage of OLIG2-positive cells in single-cell suspensions

How can I use OLIG2 antibodies for chromatin immunoprecipitation (ChIP) studies?

For successful ChIP experiments with OLIG2 antibodies:

• Sample preparation:

  • Fix cells using formaldehyde

  • Resuspend in lysis buffer

  • Sonicate to shear chromatin to approximately 200-500 bp fragments

• Immunoprecipitation:

  • Use 5 μg of OLIG2 antibody per 5 × 10^6 cells

  • Include appropriate control antibodies (e.g., normal IgG)

  • Incubate with DNA-protein complexes for 15 minutes in an ultrasonic bath

  • Capture with secondary antibody and streptavidin ferrofluid

• Analysis:

  • Purify DNA using chelating resin solution

  • Detect specific promoters (e.g., p21) by standard PCR or ChIP-seq

This approach has been validated in A172 human glioblastoma cell lines for studying OLIG2-regulated genes .

What are common issues with OLIG2 antibodies and how can I troubleshoot them?

How should I interpret OLIG2 staining in brain tumor specimens?

When analyzing OLIG2 immunostaining in brain tumors:

• Expect nuclear localization - OLIG2 is predominantly expressed in the nuclei of oligodendrocytes and oligodendroglial tumors

• Compare with other markers:

  • OLIG2 and GFAP are typically expressed in a mutually exclusive manner

  • OLIG2 expression is cell-cycle related

• Consider tumor type differentiation:

  • Oligodendroglial tumors show strong OLIG2 staining

  • Astrocytic tumors exhibit lesser OLIG2 staining

  • Statistical analysis can differentiate between oligodendroglial and astrocytic tumors

  • Neither central neurocytoma nor schwannoma cases typically show OLIG2 staining

• Note that staining intensity does not correlate with histological grade in oligodendroglial tumors

How can OLIG2 antibodies be used to study oligodendrocyte differentiation in vitro?

OLIG2 antibodies provide valuable tools for tracking oligodendrocyte development:

• Quantitative assessment of differentiation:

  • Count percentage of OLIG2-positive cells and MBP-positive oligodendrocytes

  • Classify MBP-positive cells into morphological categories representing maturation stages :

    • Stage 1: ≤3 primary processes with minimal secondary/tertiary processes

    • Stage 2: ≥3 primary processes with moderate secondary/tertiary processes

    • Stage 3: ≥5 primary processes with extensive secondary/tertiary processes

    • Stage 4: Extending myelin-like membrane structures with branched processes

• Co-localization with developmental markers:

  • OLIG2 with NG2 for oligodendrocyte precursor cells

  • OLIG2 with MBP for mature oligodendrocytes

• Time-course analysis:

  • Monitor OLIG2 expression during differentiation of neural stem/progenitor cells

  • Quantify changes at specific time points (e.g., DIV6, DIV10)

This approach has been used to characterize accelerated oligodendrocyte differentiation in Ptprz-deficient mice .

What is the significance of OLIG2 in CNS pathology studies?

OLIG2 antibodies provide critical information in several pathological contexts:

• Gliomas:

  • OLIG2 is highly expressed in malignant gliomas

  • Can help distinguish between oligodendroglial and astrocytic tumors

  • Aids in diagnosis when combined with other markers

• L-2-hydroxyglutaric aciduria:

  • In l2hgdh-/- mouse models, OLIG2 immunostaining reveals that most vacuoles are in close contact with oligodendrocyte nuclei

  • Helps identify disrupted myelin sheaths and dilated cytoplasmic organelles

• Demyelinating diseases:

  • Identifies oligodendrocyte lineage cells in lesions

  • Tracks remyelination efforts following injury

• Cortical injury:

  • OLIG2 plays a role in mediating the brain's response to cortical injury through post-injury gliosis

What are the appropriate controls for validating OLIG2 antibody specificity?

For rigorous validation of OLIG2 antibodies:

• Positive controls:

  • Normal human brain tissue with identifiable oligodendrocytes

  • Recombinant human OLIG2 protein for Western blot

  • Mouse embryo (E13) tissue sections for developmental studies

• Negative controls:

  • Primary antibody omission

  • Isotype control antibodies

  • Tissues known to lack OLIG2 expression (e.g., schwannoma)

• Specificity validation:

  • Western blotting to confirm single band at 32-35 kDa

  • RNA-protein correlation using RNAscope ISH-IHC to compare OLIG2 mRNA and protein expression

  • Antibodies raised against N-terminal portions of OLIG2 avoid cross-reactivity with OLIG3

Dual validation approaches combining protein and transcript detection provide the strongest evidence for antibody specificity.

How can OLIG2 antibodies be integrated into single-cell analysis workflows?

Single-cell analysis with OLIG2 antibodies enables high-resolution studies of oligodendrocyte lineage heterogeneity:

• Single-cell immunocytochemistry:

  • Combine OLIG2 with other lineage markers to identify cell subpopulations

  • Quantify nuclear vs. cytoplasmic OLIG2 localization at single-cell level

• Flow cytometry-based approaches:

  • Use OLIG2 antibodies in intracellular staining protocols

  • Sort OLIG2+ populations for downstream analysis

• Multi-omics integration:

  • Correlate OLIG2 protein levels with transcriptomic or epigenetic profiles

  • Identify regulatory networks governing oligodendrocyte differentiation

These approaches help elucidate heterogeneity within oligodendrocyte populations and map developmental trajectories with unprecedented resolution.

What considerations should guide experimental design when studying OLIG2 post-translational modifications?

OLIG2 function is regulated by post-translational modifications that affect its activity:

• Phosphorylation detection:

  • Consider phospho-specific antibodies for studying OLIG2 activation states

  • Design appropriate sample preparation to preserve phosphorylation status

  • Include phosphatase inhibitors in lysis buffers

• Experimental controls:

  • Use phosphatase treatments as negative controls

  • Include samples with known phosphorylation status

• Functional correlation:

  • Link phosphorylation status to DNA binding activity through ChIP assays

  • Correlate with cellular differentiation state or tumor progression